POLICY NAME Sabril (vigabatrin) POLICY # 2376P

Criteria

Criteria for Coverage for Infantile Spasms	
	Documented diagnosis of Infantile Spasms
	Used as monotherapy in pediatric patients for whom the potential benefits outweigh the potential risk of vision loss
	Age 1 month to 2 years
	Coverage of branded products require documented allergic reaction to generic vigabatrin
	Approval Time
Crit	eria for Coverage of Complex Partial Seizures
	Documented diagnosis of Complex Partial Seizures
	Member is 16 years of age
	Used as adjunctive therapy and CPS is refractory to other antiepileptic agents, such as levetiracetam, carbamazepine, zonisamide, or phenytoin
	Inadequate response to at least 2 alternative treatments for CPS, such as divalproex or valproic acid
	Coverage of branded products require documented allergic reaction to generic vigabatrin
	Approval Time • Initial Approval: 12 months